SOO KANG: Open Payments
NPI 1356983670 · FOLSOM, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,322 in 41 payments from 12 companies in 2025. Trend: 2023 $1,554 · 2024 $415 · 2025 $1,322
Food & beverage: $1,322
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 12 | $326 |
| Otsuka America Pharmaceutical, Inc. | 5 | $240 |
| Janssen Pharmaceuticals, Inc | 7 | $139 |
| Axsome Therapeutics, Inc. | 2 | $138 |
| Vanda Pharmaceuticals Inc. | 3 | $135 |
| E.R. Squibb & Sons, L.L.C. | 1 | $122 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $65 |
| Supernus Pharmaceuticals, Inc. | 3 | $57 |
| Bausch Health US, LLC | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 1 | $29 |
Products named: INGREZZA, REXULTI, Auvelity, COBENFY, FANAPT, SPRAVATO, CAPLYTA, Qelbree.
Industry payments across CA — which companies pay providers there.
